RxDoctor Payments Data

Romeo Rojas, MD

Internal Medicine · Miami, FLNPI 1730178690

Payments from drug & device makers

$7,668in general payments, 2019–2025

Across 107 payments — averaging $71.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Impulse Dynamics (USA) Inc.$1K
  • Biotronik Inc.$1K
  • Medtronic$505
  • Biosense Webster, Inc.$485
  • AstraZeneca$387
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$7,50298%
  • Education$1662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,668 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$22,663
Medicare patients
58
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$90,000
EliquisApixaban135$79,737
OzempicSemaglutide48$48,307
FarxigaDapagliflozin Propanediol28$23,093
MounjaroTirzepatide19$20,123
EntrestoSacubitril/Valsartan33$19,041
XareltoRivaroxaban26$14,447
VascepaIcosapent Ethyl31$13,504
TrulicityDulaglutide12$12,009
JanuviaSitagliptin Phosphate12$7,270
LivaloPitavastatin Calcium12$3,732
Gabapentin150$2,883
Humalog Mix 75-25Insulin Lispro Protamin/Lispro11$2,727
Carvedilol ErCarvedilol Phosphate12$2,609
Atorvastatin Calcium244$1,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$269$90,00073 claims
PfizerEliquis$196$79,737135 claims
Novo NordiskOzempic$45$48,30748 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25, Humalog, Insulin Lispro$147$36,56084 claims
AstraZenecaFarxiga$387$23,09328 claims
NovartisEntresto$63$19,04133 claims
Johnson & JohnsonXarelto$372$14,44726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →